Physician profile
Ayman Mohsen Fareed
NPI 1710997069
$1,566.01
in general payments reported to CMS, 2019-2025
14 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what 83% of Addiction Psychiatry providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.32 · 2022: $28.90 · 2023: $86.73 · 2024: $348 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $357.51 | 2019-2025 | Sublocade |
| Braeburn INC. | $324.85 | 2024-2025 | Brixadi |
| Otsuka America Pharmaceutical, INC. | $157.95 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $156.42 | 2024-2025 | Azstarys |
| Alkermes, INC. | $131.33 | 2019-2025 | Vivitrol, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $120.83 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $92.99 | 2024-2025 | Spravato |
| Tris Pharma INC | $56.39 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $48.12 | 2025 | Qelbree |
| Lundbeck LLC | $32.46 | 2025 | Rexulti |
| Abbvie INC. | $32.29 | 2023 | |
| Noven Therapeutics, LLC | $22.55 | 2025 | Secuado, Xelstrym |
| Axsome Therapeutics, INC. | $17.04 | 2025 | Auvelity |
| Vertical Pharmaceuticals, LLC | $15.28 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayman Fareed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.